Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients


Objective: To explore the association of serum tumor abnormal protein (TAP) with other serologicalbiomarkers e.g. carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen19-9 (CA19-9) and its clinical application in colorectal cancer (CRC) patients.
Methods: Patients (N=98) wereenrolled into this study with histologically or cytologically confirmed CRC. Using a test kit, the level of TAPwas determined, while chemiluminescence was used to measure the levels of some other common serologicalbiomarkers e.g. CEA, CA125 and CA19-9.
Results: The area of TAP condensed particulate matter decreased afterchemotherapy compared with before chemotherapy when CT or MRI scans showed disease control. In contrast,it increased with disease progression (P<0.05). Furthermore, a statistically significant difference was confirmed inmonitoring of TAP and common serological biomarkers e.g. CEA and CA19-9 (p<0.05).
Conclusions: DetectingTAP in CRC patients has high sensitivity and specificity and can be used as a new independent indicator forclinically monitoring CRC patients in the course of chemotherapy.